Drugs / SAL067
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06883656 | Mar → Nov 2022 | impaired renal function disease, type 2 diabetes mellitus | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05801627 | May 2020 → May 2022 | type 2 diabetes mellitus | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-07-05 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Regulatory 2型糖尿病创新药苯甲酸福格列汀片（信立汀）获批上市 salubris.com ↗
近日，信立泰宣布，糖尿病新药“苯甲酸福格列汀片”（商品名：信立汀）获得国家药品监督管理局签发的药品注册证书。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-07-05 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2型糖尿病创新药苯甲酸福格列汀片（信立汀）获批上市 salubris.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAL067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05801627 ↗ |
| Known as | Fultagliptin benzoate | “Fultagliptin benzoate is a novel and high-selective DPP-4 inhibitor.” PMID 41661440 ↗ Feb 2026 |
| Action | Inhibit | “Fultagliptin benzoate is a novel and high-selective DPP-4 inhibitor.” PMID 41661440 ↗ Feb 2026 |
| Route | Oral | “After oral administration of a single dose of fultagliptin benzoate tablets 12 mg under fasted conditions” PMID 41661440 ↗ Feb 2026 |